{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-072481","form_type":"8-K","ticker":"EMMA","cik":"0000822370","company_name":"Emmaus Life Sciences, Inc.","filed_at":"2022-11-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:53.659874+00:00","generated_at":"2026-06-21T19:08:26.415303+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Emmaus Q3 net loss narrows to $0.4M; revenue slides YoY; working capital insufficient","bullets":["Q3 net revenues $4.9M, up 15% from Q2 but down YoY from $5.8M; nine-month revenues $12.5M vs $17.6M.","Q3 net loss $0.4M ($0.01/shr) vs $3.2M loss in Q3 2021; operating loss $0.7M vs $31k.","Cash and equivalents $1.2M vs $2.3M at Dec 31; working capital insufficient for next 12 months without restructuring.","First Endari sales in UAE (approved May 2022) and early access in GCC countries boosted Q3 revenue.","Company discussing restructuring or refinancing of indebtedness and other current liabilities."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-072481","json":"https://secwatch.observer/filing/0001213900-22-072481.json","markdown":"https://secwatch.observer/filing/0001213900-22-072481.md","text":"https://secwatch.observer/filing/0001213900-22-072481.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/0001213900-22-072481-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/ea168520-8k_emmauslife.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T19:08:26.415303+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"340aad0e104309470e99071b12eda117cc00f966","claim":"Emmaus Life Sciences, Inc. reported nine months ended September 30, 2022 results: revenue $12.5 million, net income a net loss of $10.8 million, EPS $0.22 per share.","evidence_excerpt":"this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order purchases in 2022","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/0001213900-22-072481-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"nine months ended September 30, 2022"},{"label":"Revenue","value":"$12.5 million"},{"label":"Net income","value":"a net loss of $10.8 million"},{"label":"EPS","value":"$0.22 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"dc75c62b8a96c8b713d284fa7467f82e5c0e48ed","claim":"Emmaus Life Sciences, Inc. reported three months ended September 30, 2022 results: revenue $4.9 million, net income a net loss of $0.4 million, EPS $0.01 per share.","evidence_excerpt":"any transactions in this regard as they may occur.” Financial and Operating Results Net Revenues. Net revenues for the three months and nine months ended September 30, 2022 were $4.9 million and $12.5 million, respectively, compared to $5.8 million and $17.6 million, respectively, for same periods in 2021. The decrease was primarily attributable to lower bulk order","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/822370/000121390022072481/0001213900-22-072481-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"three months ended September 30, 2022"},{"label":"Revenue","value":"$4.9 million"},{"label":"Net income","value":"a net loss of $0.4 million"},{"label":"EPS","value":"$0.01 per share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}